1-3 of 3
Rien van Marwijk Kooy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Dietger Niederwieser, Dirk Hasenclever, Wolfgang E. Berdel, Bart J. Biemond, Haifa Kathrin Al-Ali, Yves Chalandon, Michel Van Gelder, Christian Junghanss, Goesta Gahrton, Mathias Haenel, Rüdiger Hehlmann, Thomas Heinicke, Andreas Hochhaus, Simona Iacobelli, Rien van Marwijk Kooy, Nicolaus Kröger, Jeroen J.W.M. Janssen, Madlen Jentzsch, Frank Breywisch, Mohamad Mohty, Stavroula Masouridi-Levrat, Gert Ossenkoppele, Jakob Passweg, Wolfram Pönisch, Johannes Schetelig, Christoph Schliemann, Sebastian Schwind, Matthias Stelljes, Peter JM Valk, Bob Lowenberg, Jan J. Cornelissen
Journal: Blood
Blood (2022) 140 (Supplement 1): 2126–2129.
https://doi.org/10.1182/blood-2022-157684
Published: 2022
Journal Articles

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Clinical Trials & Observations
Gerwin Huls, Dana A. Chitu, Violaine Havelange, Mojca Jongen-Lavrencic, Arjan A. van de Loosdrecht, Bart J. Biemond, Harm Sinnige, Beata Hodossy, Carlos Graux, Rien van Marwijk Kooy, Okke de Weerdt, Dimitri Breems, Saskia Klein, Jürgen Kuball, Dries Deeren, Wim Terpstra, Marie-Christiane Vekemans, Gert J. Ossenkoppele, Edo Vellenga, Bob Löwenberg, the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
Journal: Blood
Blood (2019) 133 (13): 1457–1464.
https://doi.org/10.1182/blood-2018-10-879866
Published: 2019
Includes: Supplemental data
Journal Articles

Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or Unlikely to Respond to Erythropoietin. Results of a HOVON89 Phase II Randomized Multicenter Study. (EudraCT 2008-002195-10)

Arjan A. van de Loosdrecht, MD PhD, Dana A Chitu, PhD, Eline MP Cremers, MD, Theresia M Westers, PhD, Canan Alhan, MD, Heleen Visser-Wisselaar, PhD, Annelies Verbrugge, Petra Muus, MD PhD, Inge de Greef, MD PhD, Pierre W Wijermans, MD, Joop H. Jansen, PhD, Saskia K. Klein, MD PhD, Edo Vellenga, MD PhD, Marie-Cecile Legdeur, MD PhD, Wendy Deenik, MD PhD, Mojca jongen-Lavrencic, MD PhD, Rien van Marwijk-Kooy, Bea Tanis, MD PhD, Jurgen Wegman, Tanja van Maanen, Gert Ossenkoppele, MD PhD
Journal: Blood
Blood (2016) 128 (22): 224.
https://doi.org/10.1182/blood.V128.22.224.224
Published: 2016